Related Experiment Videos
Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available
Cancer Treatment Reports
|September 1, 1987
Summary
This study compared medroxyprogesterone acetate (MPA) breast cancer treatments. Provera demonstrated higher MPA concentrations than Farlutal, suggesting differences in bioavailability for effective treatment.
Area of Science:
- Oncology
- Pharmacokinetics
- Endocrinology
Background:
- Medroxyprogesterone acetate (MPA) is used for breast cancer treatment.
- Assessing the bioavailability of different MPA formulations is crucial for therapeutic efficacy.
Purpose of the Study:
- To compare the serum concentrations and bioavailability of two oral medroxyprogesterone acetate (MPA) formulations in patients with advanced breast cancer.
Main Methods:
- Twenty-nine female patients with metastatic or recurrent breast cancer received 1g of oral MPA daily.
- Serum MPA concentrations were monitored over a 28-day period to determine pharmacokinetic parameters.
Main Results:
- Provera (100- and 200-mg tablets) showed significantly higher area-under-the-concentration-time curve, peak, and steady-state MPA concentrations compared to Farlutal (500-mg tablets).
- This indicates a greater relative bioavailability for Provera.
Conclusions:
- Significant differences in relative bioavailability exist between Provera and Farlutal MPA formulations.
- Healthcare providers should consider these bioavailability differences when prescribing MPA or evaluating treatment outcomes in breast cancer patients.